Pulmozyme in Cystic Fibrosis With Sinusitis

Phase 3 Withdrawn Milton S. Hershey Medical Center Genentech, Inc. · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

The hypothesis is that the intranasal use of Pulmozyme will decrease the severity of sinusitis in Cystic Fibrosis and lead to an improved quality of life.

Timeline

Start: 2013-07
Primary completion: 2014-06
Completion: 2015-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dornase alfa	Protein / enzyme biologic	2.5 mg	Intranasal

Pulmozyme in Cystic Fibrosis With Sinusitis

Summary

Timeline

Drugs

Indications